Vcanbio Cell & Gene Engineering Corp

Vcanbio Cell & Gene Engineering Corp Long-term Debt

The Long-Term Debt of Vcanbio Cell & Gene Engineering Corp (600645.SS) as of Oct 16, 2026 is 9.46 M CNY. In the previous year, Long-Term Debt was 15.77 M CNY — a change of -40.00% (lower).

Long-term Debt

9.46 MCNY

YoY

-40.00%

Last updated:

Long-Term Debt of Vcanbio Cell & Gene Engineering Corp is 2023 9.46 M CNY. Long-Term Debt of Vcanbio Cell & Gene Engineering Corp was 2022 15.77 M CNY. It decreases by -40.00% lower compared to the previous year.

The Vcanbio Cell & Gene Engineering Corp Long-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Long-term Debt
Date
Long-term Debt
Jan 1, 2016
88.24 M CNY
Jan 1, 2017
181.46 M CNY
Jan 1, 2018
156.72 M CNY
Jan 1, 2019
46.30 M CNY
Jan 1, 2020
37.53 M CNY
Jan 1, 2021
22.08 M CNY
Jan 1, 2022
15.77 M CNY
Jan 1, 2023
9.46 M CNY
The Vcanbio Cell & Gene Engineering Corp Long-term Debt history
YEARLong-term DebtYoY
9.46 MCNY-40.00%
15.77 MCNY-28.57%
22.08 MCNY-41.17%
37.53 MCNY-18.93%
46.30 MCNY-70.46%
156.72 MCNY-13.63%
181.46 MCNY+105.64%
88.24 MCNY+135.31%
37.50 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vcanbio Cell & Gene Engineering Corp Stock analysis

What does Vcanbio Cell & Gene Engineering Corp do? Vcanbio Cell & Gene Engineering Corp Ltd is a biotechnology company based in Tianjin, China, operating within the healthcare sector. The company has been publicly traded since its IPO on May 4, 1993, and is listed under the ticker 600645.SS with ISIN CNE000000545. It employs 2,332 full-time staff and focuses on the development of life sciences technology. Vcanbio engages in cell culture, gene detection, and storage services, as well as the production and sale of cytokines culture solutions, cosmetics, and detection reagents. The company primarily serves domestic markets in China, with its headquarters located in Tianjin. Its website is http://www.vcanbio.com. The firm's business activities include the development and application of biotechnology solutions, though specific details on product names, acquisitions, or additional financial figures are not provided in the available information. Vcanbio operates as a public company with a presence in the Chinese biotechnology industry, emphasizing innovation in cell and gene engineering. Vcanbio Cell & Gene Engineering Corp is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vcanbio Cell & Gene Engineering Corp stock

Long-Term Debt of Vcanbio Cell & Gene Engineering Corp is 9.46 M CNY in 2023.

Long-Term Debt of Vcanbio Cell & Gene Engineering Corp changed from 15.77 M CNY to 9.46 M CNY, representing a -40.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt Vcanbio Cell & Gene Engineering Corp since 2006 – with annual values, charts, and detailed analysis.

Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.

Long-Term Debt's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's Vcanbio Cell & Gene Engineering Corp historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Vcanbio Cell & Gene Engineering Corp

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Vcanbio Cell & Gene Engineering Corp